Haematoncology Flashcards

1
Q

Cancer stem cells accumulate leading to a

A

constant supply of malignant clone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

clonal disorder originates from

A

a single progenitor cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Point mutations include

A

missense
non-sense
frameshift

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Translocation mutations include

A

chimeric genes/proteins

overexpression of a normal cellular gene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Genetic abnormalities include

A

poijnt mutations
duplications
translocations
gene and chromosomal deletions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mutated cells acquire characteristics of what cell

A

stem cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what do mutated cells lead to

A

population expansion and avoidance of cell death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Myeloma is the clonal disorder of what cell

A

plasma cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what does MGUS mean

A

monoclonal gammopathy of undetermined experience

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what antigen experience in myeloma

A

igG or IgA
IgM
kappa/lamda light chain restrictions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

5 things in the anatomy of a plasma cell

A
perinuclear halo/Golgi zone 
Eccentric nucleus 
Clock face nucleus 
Oval cell shape 
Basophilic cytoplasm
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what are the drivers of clonal evolution

A

Clonal competition
Tumour microenvironment
Treatment Immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Initiation in Post - GC Bcell what happens

A

hyperdiploidy

IgH translocations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MGUS to -smm to MM progression inlcudes

A

KRAS mutation
MYC activation
Genomic instability
TP53 inactivation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MM to EMD progression

A

secondary genetic events
pattern of mutations
Del (17p) TP53

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Clinical Presentations of Myeloma

A
Normocytic normochromic anaemia (75%)
Bone pain (60%)
Fatigue (30%)
Weight loss (25%)
Renal impairment (15%)
Hyperviscosity 
Recurrent infection s
17
Q

Myeloma is an

A

incurable lymphoid malignancy of post germinal centre of origin

18
Q

Typical findings on a blood film from a patient with myeloma

A

Rouleaux, background staining and in this case thrombocytopenia

19
Q

In blood findings of myeloma the results present and increase in

A

circulating immunoglobulin

20
Q

Bone marrow in myeloma will present

A

an accumulation of malignant plasma cells

21
Q

What components can be use to diagnose the condition of myeloma

A

secretion of immunoglobulin

22
Q

When do Bence jones appear in urine

A

Failure to filter free light chains

23
Q

The 4 things that make up CRAB criteria

A

Hypercalcaemia

Renal impairment = formation o frenal cast; Tamm Horsfall protein

Anaemia

Bone lesions - lytic lesions and pathological fractures

24
Q

What is a frequent finding of patients with myeloma

A

Punched out lesions and fractures

25
Appearance of bone lesions
soft and gelatinous like fish flesh
26
stromal cells have the affect of
greatly promoting the growth, survival, drug resistance and migration of myeloma.
27
myeloma cells induce stromal cells to
to produce RANKL and interleukin -6 which induce proliferation of osteoblasts
28
Myeloma cells also produce what inhibitory factors
DKK1, IL-3, soluble frizzle-related protein-2 and IL-7, which suppress osteoblast differentiation and new bone formation. DKK1, Dickkopf; IL, interleukin.
29
myeloma produces what activating factors
Myeloma cells produce factors that directly or indirectly activate osteoclasts, such as macrophage inflammatory protein-1α and IL-3.